Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1

Abstract

Background: Chemotherapy dose modification to manage adverse events is commonplace in clinical practice. This exploratory analysis evaluates the impact of liposomal irinotecan dose modification on overall survival (OS) and progression-free survival (PFS) in the NAPOLI-1 clinical trial (NCT01494506).

Methods: Analysis includes only patients enrolled under protocol version 2 who received at least the first 2 scheduled doses of study drug. Within the liposomal irinotecan +5 fluorouracil/leucovorin (5 FU/LV) arm, patients were grouped according to whether or not they had a dose modification within the first 6 weeks. Dose reduction was defined as any decrease from initial dose; dose delay was any dosing delay >3 days from target date. OS and PFS (Kaplan-Meier estimates) were compared within the liposomal irinotecan+5-FU/LV arm and between treatment arms. Unstratified hazard ratios (HRs) were calculated using Cox regression analysis.

Results: Of the 93 patients from the liposomal irinotecan+5 FU/LV arm included in the analysis, 53 experienced a dose modification (both delay and reduction, n = 30; delay only, n = 19; reduction only, n = 4). No apparent difference in median OS or PFS was observed between patients who did versus patients who did not have a dose modification (OS: 8.4 vs 6.7 months; HR, 0.89; PFS: 4.2 vs 3.1 months; HR, 0.74).

Conclusion: An early dose reduction or delay of liposomal irinotecan+5-FU/LV in the first 6 weeks does not significantly impact OS or PFS compared to patients without dose modifications. This finding suggests that tolerability-guided dose modification of liposomal irinotecan does not adversely affect efficacy outcomes.

Keywords: Dose modification; Liposomal irinotecan; NAPOLI-1; Or phrases: metastatic pancreatic ductal adenocarcinoma; mPDAC.

Conflict of interest statement

Declaration of competing interest Li-Tzong Chen: Bristol-Myers Squibb, Five Prime Therapeutics, Lilly, Merrimack, MSD, Novartis, Ono Pharmaceutical, PharmaEngine, Syncope, Taiwan, TTY Biopharm (C/A); GlaxoSmithKline, Merck Serono, Novartis, Polaris (Inst); TTY Biopharm (Inst, RF); Anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan (I/P). Teresa Macarulla: Nothing to disclose. Jean-Frédéric Blanc: Baxalta/Shire, Bayer Schering Pharma, Gilead Sciences (H); Baxalta/Shire, Bristol-Myers Squibb, Novartis, Onxeo (C/A); Bayer Schering Pharma (ET. Beloo Mirakhur: Ipsen (E); Bristol-Myers Squibb (OI). Floris A. de Jong: Servier (E); Shire (OI). Bruce Belanger: Ipsen, Merrimack (E). Tanios Bekaii-Saab: Amgen, Bayer, Boehringer Ingelheim, Celgene, Genentech/Roche, Glenmark, Lilly, Merrimack, NCCN, Pfizer, Research to Practice, Sirtex Medical, Taiho Pharmaceutical (C/A); Exelixis, Merck, Polaris (Other Relationship). Jens T. Siveke: Baxalta, Celgene, Lilly, Shire (C/A); 4SC, Bristol-Myers Squibb, Celgene (RF); Celgene; Roche; Shire (T/Exp).

Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.